KalVista Pharmaceuticals

101 articles with KalVista Pharmaceuticals

• KalVista Pharmaceuticals Announces Non-Proprietary Name Selection for KVD900

  5/17/2022

  KalVista Pharmaceuticals, Inc. announced that the proposed name “sebetralstat” has been approved by the World Health Organization’s International Nonproprietary Names Expert Committee and the American Medical Association’s United States Adopted Names Council for the drug candidate formerly known as KVD900.

• KalVista Pharmaceuticals to Present at 21st Annual Needham Virtual Healthcare Conference

  4/11/2022

  KalVista Pharmaceuticals to Present at 21st Annual Needham Virtual Healthcare Conference.

• KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 04, 2022

  4/4/2022

  KalVista Pharmaceuticals, Inc., announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate of 7,000 shares of KalVista common stock on April 1, 2022 as inducement material to such employee entering into employment with KalVista.

• KalVista Announces Publication of Additional KVD900 Data in Clinical & Experimental Allergy

  3/22/2022

  KalVista Announces Publication of Additional KVD900 Data in Clinical & Experimental Allergy.

• KalVista Pharmaceuticals Reports Third Fiscal Quarter 2022 Results

  3/10/2022

  KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, provided an operational update and released financial results for the third fiscal quarter ended January 31, 2022.

• KalVista Pharmaceuticals Announces Initiation of KVD900 Phase 3 KONFIDENT Clinical Trial

  3/7/2022

  KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the initiation of the Phase 3 KONFIDENT clinical trial evaluating the efficacy and safety of KVD900 as the first potential oral, on-demand therapy for hereditary angioedema (HAE) attacks.

• KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 03, 2022

  3/3/2022

  KalVista Pharmaceuticals, Inc., announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate of 5,000 shares of KalVista common stock on March 1, 2022 as inducement material to such employee entering into employment with KalVista.

• KalVista Pharmaceuticals Presents Data Showing Rapid Reduction of Plasma Kallikrein Activity After Oral KVD900 Treatment and Early Symptom Relief From HAE Attacks in Patients

  2/28/2022

  KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today presented data for its lead oral drug candidate, KVD900, in development for on-demand treatment of hereditary angioedema (HAE), at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Scientific Meeting.

• KalVista Pharmaceuticals to Present Data on Oral On-Demand HAE Therapy KVD900 at AAAAI 2022

  2/2/2022

  KalVista Pharmaceuticals, Inc. announced that new data on KVD900, KalVista’s lead drug program for oral on-demand treatment of hereditary angioedema attacks, will be presented at the American Academy of Allergy, Asthma & Immunology Annual Scientific Meeting 2022, taking place in Phoenix, AZ and virtually, from February 25-28, 2022.

• KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 02, 2022

  2/2/2022

  KalVista Pharmaceuticals, Inc., announced that the compensation committee of KalVista’s board of directors granted four newly-hired employees inducement options to purchase an aggregate of 19,000 shares of KalVista common stock on February 1, 2022 as inducements material to each employee entering into employment with KalVista.

• KalVista Pharmaceuticals Announces Publication of Oral HAE Therapy KVD900 Phase 1 Data in Journal of Allergy and Clinical Immunology

  1/24/2022

  KalVista Pharmaceuticals Announces Publication of Oral HAE Therapy KVD900 Phase 1 Data in Journal of Allergy and Clinical Immunology

• KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  1/4/2022

  KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted four newly-hired employees inducement options to purchase an aggregate of 23,000 shares of KalVista common stock on January 3, 2022 as inducements material to each employee entering into employment with KalVista.

• KalVista Pharmaceuticals Reports Second Fiscal Quarter Results

  12/9/2021

  KalVista Pharmaceuticals, Inc. today provided an operational update and released financial results for the second fiscal quarter ended October 31, 2021.

• KalVista Pharmaceuticals Reported Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  12/3/2021

  KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted six newly-hired employees inducement options to purchase an aggregate of 18,000 shares of KalVista common stock on December 1, 2021 as inducements material to each employee entering into employment with KalVista.

• KalVista Pharmaceuticals Provides Progress Update on KVD900 for Oral On-Demand Treatment of Hereditary Angioedema

  11/10/2021

  KalVista Pharmaceuticals, Inc. today provided an update on the clinical trial progress for KVD900 in development for oral on-demand treatment of hereditary angioedema (HAE).

• KalVista Pharmaceuticals to Present at Upcoming Investor Conferences - Nov 09, 2021

  11/9/2021

  KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced it will participate in a fireside chat at the following investor conferences.

• KalVista Pharmaceuticals Presents Data Demonstrating KVD900 Achieves Rapid Exposure and Improves Outcomes as Oral On-Demand Treatment of HAE

  11/8/2021

  KalVista Pharmaceuticals, Inc. today announced data presented at American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

• KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 04, 2021

  11/4/2021

  KalVista Pharmaceuticals, Inc., announced that the compensation committee of KalVista’s board of directors granted six newly-hired employees inducement options to purchase an aggregate of 23,000 shares of KalVista common stock on November 3, 2021 as inducements material to each employee entering into employment with KalVista.

• KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 04, 2021

  10/4/2021

  KalVista Pharmaceuticals, Inc., announced that the compensation committee of KalVista’s board of directors granted six newly-hired employees inducement options to purchase an aggregate of 40,000 shares of KalVista common stock on October 1, 2021 as inducements material to each employee entering into employment with KalVista.

• KalVista Pharmaceuticals to Present at Cantor Virtual Global Healthcare Conference

  9/21/2021

  KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced it will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 8:40 a.m. ET.